A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma
Latest Information Update: 23 May 2025
At a glance
- Drugs Etrumadenant (Primary) ; Zimberelimab (Primary)
- Indications Liposarcoma
- Focus Therapeutic Use
Most Recent Events
- 15 May 2025 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2023 New trial record